Evidence map›Paper›PMID 23578591›Full record

ArticleJournal of autoimmunity2013

Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway.

Jing Wen, Yumin Xia, Ariel Stock, Jennifer S Michaelson, Linda C Burkly, Maria Gulinello, Chaim Putterman

Open access · greenAbstract read
In one paragraph

Article in Journal of autoimmunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jing WenThe Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Yumin Xia
Ariel Stock
Jennifer S Michaelson
Linda C Burkly
Maria Gulinello
Chaim Putterman
Albert Einstein College of Medicine · USBiogen (United States) · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007288 · NIGMS · YESHIVA UNIVERSITY · PI AKABAS, MYLES H. · 1985 to 2022
$35.6M
The Renal Pathogenicity of anti-DNA AntibodiesR01AR048692 · NIAMS · YESHIVA UNIVERSITY · PI PUTTERMAN, CHAIM · 2002 to 2013
$4.0M
TNF-like weak inducer of apoptosis (TWEAK) signaling in lupus nephritisR01DK090319 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI PUTTERMAN, CHAIM · 2011 to 2014
$1.5M
NIAMS NIH HHS R01 AR048692NIAMS NIH HHS R01 AR048693NIDDK NIH HHS R01 DK090319NIGMS NIH HHS T32 GM007288
6 · The paper itself

Abstract

Given the early onset of neuropsychiatric disease and the potential response to immunosuppressive therapy, neuropsychiatric disease is considered a primary disease manifestation in systemic lupus erythematosus (SLE). However, the pathogenesis is not fully understood and optimal treatment has yet to be determined. TWEAK is a TNF family ligand that mediates pleotropic effects through its receptor Fn14, including the stimulation of inflammatory cytokine production by astrocytes, endothelial cells, and other non-hematopeotic cell types, and induction of neuronal death. Furthermore, TWEAK-inducible mediators are implicated in neuropsychiatric lupus. Thus, we hypothesized that the TWEAK/Fn14 pathway may be involved in the pathogenesis of neuropsychiatric SLE. We generated MRL-lpr/lpr (MRL/lpr) mice deficient for Fn14, the sole known signaling receptor for TWEAK. Neuropsychiatric disease was compared in age- and gender-matched MRL/lpr Fn14 wild type (WT) and knockout (KO) mice, using a comprehensive battery of neurobehavioral tests. We found that MRL/lpr Fn14WT mice displayed profound depression-like behavior as seen by increased immobility in a forced swim test and loss of preference for sweetened fluids, which were significantly ameliorated in Fn14KO mice. Similarly, MRL/lpr Fn14WT mice had impaired cognition, and this was significantly improved in Fn14KO mice. To determine the mechanism by which Fn14 deficiency ameliorates neuropsychiatric disease, we assessed the serum levels of autoantibodies and local expression of cytokines in the cortex and hippocampus of lupus mice. No significant differences were found in the serum levels of antibodies to nuclear antigens, or autoantibodies specifically associated with neuropsychiatric disease, between MRL/lpr Fn14WT and KO mice. However, MRL/lpr Fn14KO mice had significantly decreased brain expression of RANTES, C3, and other proinflammatory mediators. Furthermore, MRL/lpr Fn14KO mice displayed improved blood brain barrier integrity. In conclusion, several central manifestations of neuropsychiatric lupus, including depression-like behavior and altered cognition, are normalized in MRL/lpr mice lacking Fn14. Our results are the first to indicate a role for the TWEAK/Fn14 pathway in the pathogenesis of neuropsychiatric lupus, and suggest this ligand-receptor pair as a potential therapeutic target for a common and dangerous disease manifestation.

Indexed as

AnimalsAutoantibodiesBlood-Brain BarrierBrainCognition DisordersCytokine TWEAKDepressionDisease Models, AnimalFemaleInflammation MediatorsLupus Vasculitis, Central Nervous SystemMiceMice, Inbred MRL lprMice, KnockoutNeuroimmunomodulationReceptors, Tumor Necrosis FactorAutoantibodiesCytokine TWEAKInflammation MediatorsReceptors, Tumor Necrosis FactorTnfrsf12a protein, mouseTnfsf12 protein, mouseTumor Necrosis FactorsTWEAK Receptor

Identifiers

PMID23578591
PMCPMC3672366
OpenAlexW2118495715

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.